Security
ZEO SCIENTIFIX INC · BPSR
BPSRNYSE_AMERICANCommon stockHistorical · closed Nov 5, 2021CIK 1557376Updated Nov 2, 2026
Name history
Organicell Regenerative Medicine, Inc. · through Jan 29, 2024Biotech Products Services & Research, Inc. · through Jun 15, 2018BESPOKE TRICYCLES INC · through Sep 14, 2015
Current security for this SEC filerZEOX · OTC
BPSR price & chart
Historical security
This listing closed Nov 5, 2021. Live provider charts are shown only for current listings.
Current security: ZEOX
About the company
We are a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company’s proprietary products, including Zofin™, are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and Patient Pure X™ (“PPX™”), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient’s own peripheral blood (“RAAM Products”).
In the news
No coverage from other publishers is available.
Recent filings
Other Events
Items 8.01, 9.01
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities
Items 1.01, 3.02, 9.01
Entry into a Material Definitive Agreement
Items 1.01, 9.01
10-KT filing
NT 10-K filing
Show 5 more recent filings
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 5.03
Other Events
Items 8.01, 9.01
NT 10-Q filing
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
Financials
FY 2026 · USDSource
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2026 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 1,652,000Source | 2,221,000Source | 3,886,000Source | 1,435,000Source | 1,932,000Source | 2,571,000Source | 1,550,000Source | 2,432,000Source | 4,098,000Source | 1,643,000Source | 2,782,200Source | 6,200,688Source |
| Property, Plant and Equipment, NetUSD | 589,000Source | 496,000Source | 609,000Source | 570,000Source | 514,000Source | 564,000Source | 460,000Source | 533,000Source | 595,000Source | 478,000Source | 572,726Source | 1,683,516Source |
| Current assets: | ||||||||||||
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 19,000Source | 276,000Source | 11,000Source | 60,000Source | 63,000Source | 6,000Source | 77,000Source | 245,000Source | 194,000Source | 18,212Source | 55,110Source |
| Inventory, NetUSD | 258,000Source | 250,000Source | 686,000Source | 235,000Source | 272,000Source | 502,000Source | 245,000Source | 316,000Source | 796,000Source | 232,000Source | 310,183Source | 248,510Source |
| Assets, CurrentUSD | 1,063,000Source | 1,725,000Source | 3,266,000Source | 865,000Source | 1,418,000Source | 2,007,000Source | 1,090,000Source | 1,892,000Source | 3,485,000Source | 1,165,000Source | 2,202,159Source | 4,366,241Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 3,966,000Source | 3,643,000Source | 3,174,000Source | 3,535,000Source | 3,632,000Source | 2,954,000Source | 3,355,000Source | 3,940,000Source | 3,479,000Source | 3,296,000Source | 4,023,219Source | 4,312,084Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 6,000Source | 6,000Source | 8,000Source | 6,000Source | 6,000Source | 8,000Source | 6,000Source | 6,000Source | 8,000Source | 6,000Source | 7,284Source | 1,479,126Source |
| Additional Paid in CapitalUSD | 64,599,000Source | 59,531,000Source | 69,435,000Source | 62,741,000Source | 58,241,000Source | 68,195,000Source | 61,645,000Source | 57,034,000Source | 73,383,000Source | 60,554,000Source | 56,259,711Source | 50,930,784Source |
| Retained Earnings (Accumulated Deficit)USD | -66,919,000Source | -60,959,000Source | -68,731,000Source | -64,847,000Source | -59,947,000Source | -68,586,000Source | -63,456,000Source | -58,548,000Source | -72,808,000Source | -62,213,000Source | -57,508,014Source | -50,521,306Source |
| Stockholders' Equity Attributable to ParentUSD | -2,314,000Source | -1,422,000Source | 712,000Source | -2,100,000Source | -1,700,000Source | -383,000Source | -1,805,000Source | -1,508,000Source | 583,000Source | -1,653,000Source | -1,241,019Source | 1,888,604Source |
| Liabilities and EquityUSD | 1,652,000Source | 2,221,000Source | 3,886,000Source | 1,435,000Source | 1,932,000Source | 2,571,000Source | 1,550,000Source | 2,432,000Source | 4,098,000Source | 1,643,000Source | 2,782,200Source | 6,200,688Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 3,875,000Source | 3,634,000Source | 3,111,000Source | 3,453,000Source | 3,621,000Source | 2,886,000Source | 3,349,000Source | 3,923,000Source | 3,420,000Source | 3,288,000Source | 4,010,085Source | 4,063,156Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 82,407Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 28,588Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | 36,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 165,000Source | 309,778Source | 309,260Source | 302,447Source |
| Long-term Debt, Current MaturitiesUSD | 698,000Source | 674,000Source | 247,000Source | 692,000Source | 669,000Source | 245,000Source | 686,000Source | 663,000Source | 248,000Source | 680,000Source | 656,853Source | — |
| Long-term Debt | — | —Source | — | — | —Source | — | — | —Source | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2026 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -2,072,000Source | -1,012,000Source | -145,000Source | -1,391,000Source | -852,000Source | -1,243,000Source | — | -4,705,000Source | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 19,000Source | 18,000Source | — | 74,000Source | 486,354Source | 332,508Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | 590,000Source | 1,096,000Source | 592,000Source | 1,091,000Source | — | 3,853,000Source | 3,208,776Source | 3,916,590Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 27,000Source | -188,000Source | — | 185,000Source | -36,898Source | -17,148Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 79,000Source | 14,000Source | — | -78,000Source | 61,673Source | 51,138Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | -216,720Source | -734,650Source | 5,484,844Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -471,000Source | 65,000Source | — | -1,450,000Source | -2,197,275Source | -3,165,840Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -14,000Source | — | — | -45,000Source | 615,566Source | -824,743Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 14,000Source | — | — | — | 25,391Source | 824,743Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 1,294,000Source | -2,000Source | — | 396,000Source | -415,186Source | 7,635,110Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 314,000Source | 1,105,000Source | 1,846,000Source | 542,000Source | 1,030,000Source | 720,000Source | 2,265,000Source | 657,000Source | 1,756,202Source | 3,753,097Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | 68,000Source | 67,145Source | 78,625Source |
| Additional Financial Items | ||||||||||||
| AmortizationUSD | — | — | — | 0Source | — | — | — | — | — | 0Source | 379,970Source | 250,472Source |
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 100,211Source | 35,789Source |
| DepreciationUSD | — | — | 19,000Source | 18,000Source | 19,000Source | 16,000Source | 19,000Source | 18,000Source | — | 74,000Source | 106,384Source | 82,036Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | — | -36,219Source | — |
| Gain (Loss) on Disposition of Assets for Financial Service OperationsUSD | — | — | — | — | — | — | — | — | — | — | 340,611Source | — |
| General and Administrative ExpenseUSD | — | — | 3,149,000Source | 2,083,000Source | 2,567,000Source | 2,287,000Source | 2,043,000Source | 2,152,000Source | — | 9,095,000Source | 10,817,627Source | 14,580,434Source |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | — | — | — | 37,455Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,072,000Source | -1,012,000Source | -145,000Source | -1,391,000Source | -852,000Source | -1,243,000Source | — | -4,705,000Source | -6,986,708Source | -8,896,557Source |
| Nonoperating Income (Expense)USD | — | — | 22,000Source | 224,000Source | — | 24,000Source | 25,000Source | 10,000Source | — | 613,000Source | — | — |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 29,670Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | -22,000Source | 3,000Source | — | — | — | 751,000Source | -10,000Source | 249,504Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 1,300,000Source | — | — | 500,000Source | 100,000Source | 7,270,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 1,306,000Source | 1,091,000Source | 2,581,000Source | 1,149,000Source | 1,446,000Source | 1,090,000Source | 4,620,000Source | 4,558,278Source | 6,491,008Source | 5,597,487Source |
| Cost of RevenueUSD | — | — | 228,000Source | 176,000Source | 526,000Source | 256,000Source | 281,000Source | 191,000Source | 844,000Source | 507,629Source | 753,534Source | 547,881Source |
| Operating Income (Loss)USD | — | — | -2,071,000Source | -1,168,000Source | -512,000Source | -1,394,000Source | -878,000Source | -1,253,000Source | -5,319,000Source | -6,766,978Source | -8,842,960Source | -12,744,103Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | -22,000Source | 3,000Source | — | — | 751,000Source | -10,000Source | 249,504Source | 25,477Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | -8,896,557Source | -12,756,560Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,072,000Source | -1,012,000Source | -145,000Source | -1,391,000Source | -852,000Source | -1,243,000Source | -4,705,000Source | -6,986,708Source | -8,896,557Source | -12,756,560Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.32Source | -0.16Source | -0.02Source | -0.22Source | -0.12Source | -0.2Source | -0.74Source | -0.99Source | — | — |
| Earnings Per Share, DilutedUSD per share | — | — | -0.32Source | -0.16Source | -0.02Source | -0.22Source | -0.12Source | -0.2Source | -0.74Source | -0.99Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 6,405,443Source | 6,259,975Source | 7,757,469Source | 6,344,817Source | 7,021,599Source | 6,344,817Source | 6,336,392Source | 7,028,638Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 6,405,443Source | 6,259,975Source | 7,757,469Source | 6,344,817Source | 7,021,599Source | 6,344,817Source | 6,336,392Source | 7,028,638Source | — | — |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| General and Administrative ExpenseUSD | — | — | 3,149,000Source | 2,083,000Source | 2,567,000Source | 2,287,000Source | 2,043,000Source | 2,152,000Source | 9,095,000Source | 10,817,627Source | 14,580,434Source | 17,793,709Source |
| Gross ProfitUSD | — | — | 1,078,000Source | 915,000Source | 2,055,000Source | 893,000Source | 1,165,000Source | 899,000Source | 3,776,000Source | 4,050,649Source | 5,737,474Source | 5,049,606Source |
| Interest ExpenseUSD | — | — | 23,000Source | 23,000Source | 11,000Source | 21,000Source | 10,000Source | 22,000Source | 92,000Source | 431,424Source | 398,260Source | — |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | — | -37,934Source |
| Labor and Related ExpenseUSD | — | — | — | — | 204,000Source | 39,000Source | 161,000Source | -4,000Source | 208,000Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | 22,000Source | 224,000Source | — | 24,000Source | 25,000Source | 10,000Source | 613,000Source | — | — | — |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 29,670Source | 38,037Source |
| Other IncomeUSD | — | — | 3,000Source | 3,000Source | — | 5,000Source | 17,000Source | — | 10,000Source | — | — | — |
| Research and Development ExpenseUSD | — | — | — | 75,000Source | 31,000Source | 42,000Source | 19,000Source | 6,000Source | 164,000Source | 922,700Source | 791,326Source | 1,120,067Source |
Offerings
Registration 333-286105
Filing attachments
zeoscientifix_ex99-1.htm · 8-K · 2026-11-03
Exhibit 99.1 FOR IMMEDIATE RELEASE ZEO ScientifiX Makes Industry History as First Facility to Achieve AABB’s Newly Established Quality Management Systems Certification Landmark industry-first certification reinforces ZEO’s leadership in manufacturing quality, independent oversight, and the rapidly expanding U.S. regenerative medicine industry. FORT LAUDERDALE, FL - November 3, 2026 - ZEO ScientifiX, Inc. (OTCQB: ZEOX) (“ZEO” or the “Company”), a biotechnology company focused on the developme…
Read attachment ↗zeoscientifix_ex99-1.htm · 8-K · 2026-10-26
Exhibit 99.1 JOINT PRESS RELEASE Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine Partnership combines Pluri’s proprietary cell technology and clinical-development experience with ZEO’s biologics manufacturing expertise, established physician network, and sales, marketing, and educational infrastructure Established U.S. commercial platform: ZEO contributes biologics manufacturing, scientific expertise, an existing product portf…
Read attachment ↗zeoscientifix_ex99-1.htm · 8-K · 2026-09-15
EX-99.1 2 zeoscientifix_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ZEO ScientifiX Plans Expansion into Georgia and Tennessee as New Regenerative Medicine Laws Take Effect Company looks to broaden its Southeast presence to support healthcare providers navigating newly enacted state laws providing for certain stem cell and regenerative medicine therapies. DAVIE, FLORIDA - September 15, 2026 - ZEO ScientifiX, Inc. (OTCQB: ZEOX) (“ZEO ScientifiX” or the “Company”) today announced its planned expans…
Read attachment ↗zeoscientifix_ex99-1.htm · 8-K · 2026-09-01
EX-99.1 2 zeoscientifix_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ZEO ScientifiX Announces Multidisciplinary Expert Faculty Lineup for the ZEO Xperience Leading physicians, scientists, regulatory experts, and healthcare innovators will convene October 23 - 25 at Fort Lauderdale’s Pier Sixty-Six Resort + Marina for three days of regenerative medicine education, hands-on clinical training, and interdisciplinary collaboration. FORT LAUDERDALE, FLORIDA - September 1, 2026 - ZEO ScientifiX, Inc. (O…
Read attachment ↗zeoscientifix_ex99-1.htm · 8-K · 2026-08-04
EX-99.1 2 zeoscientifix_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ZEO ScientifiX Launches First-of-Its-Kind ZEO Xperience, a Three-Day Immersive Regenerative Medicine Experience for Healthcare Professionals Hosted at Fort Lauderdale’s newly reimagined Pier Sixty-Six Resort, the inaugural event combines cutting-edge biologics education, hands-on clinical training, practice growth strategies, and latest innovations. DAVIE, FLORIDA - August 4, 2026 - ZEO ScientifiX, Inc. (OTCQB: ZEOX) (“ZEO Scie…
Read attachment ↗zeoscientifix_ex107.htm · S-8 · 2026-07-24
Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type)N/A Zeo ScientifiX, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Security Fee Amount Proposed Maximum Fee Rate Amount of Type Class Title Calculation …
Read attachment ↗